<?xml version="1.0" encoding="UTF-8"?>
<Label drug="betaxolol" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  The following adverse reactions have been reported in clinical trials with Betaxolol Hydrochloride Ophthalmic Solution.



   Ocular:  Discomfort of short duration was experienced by one in four patients, but none discontinued therapy; occasional tearing has been reported. Rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctate staining, keratitis, anisocoria, edema, and photophobia have been reported.



 Additional medical events reported with other formulations of betaxolol include blurred vision, foreign body sensation, dryness of the eyes, inflammation, discharge, ocular pain, decreased visual acuity, and crusty lashes.



   Systemic:  Systemic reactions following administration of Betaxolol Hydrochloride Ophthalmic Solution 0.5% or Betaxolol Hydrochloride Ophthalmic Suspension 0.25% have been rarely reported. These include:



   Cardiovascular:  Bradycardia, heart block and congestive failure.



   Pulmonary:  Pulmonary distress characterized by dyspnea, bronchospasm, thickened bronchial secretions, asthma and respiratory failure.



   Central Nervous System:  Insomnia, dizziness, vertigo, headaches, depression, lethargy, and increase in signs and symptoms of myasthenia gravis.



   Other:  Hives, toxic epidermal necrolysis, hair loss and glossitis.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
